Skip to main content
Top
Published in: Pain and Therapy 2/2016

Open Access 01-12-2016 | Original Research

How Resistant to Tampering are Codeine Containing Analgesics on the Market? Assessing the Potential for Opioid Extraction

Authors: Andreas Kimergård, Paolo Deluca, Peter Hindersson, Torben Breindahl

Published in: Pain and Therapy | Issue 2/2016

Login to get access

Abstract

Introduction

Misuse of opioid analgesics, in combination with diversion, dependence, and fatal overdoses, presents a serious problem for public health, which affects many countries worldwide. Within this context, tampering with opioids has been associated with serious harm. The aim of the present study was to assess the tampering potential of codeine combination analgesics on the market (containing codeine/non-opioid analgesics) by the extraction of codeine.

Methods

Codeine was extracted from three combination formulations sold lawfully from licensed pharmacies without a medical prescription in Denmark and the UK. Extraction of codeine followed tampering procedures available on the Internet. The amounts of codeine and accompanying non-opioid analgesics in tampering products were analysed with liquid chromatography and tandem mass spectrometry (LC–MS/MS).

Results

LC–MS/MS showed recoveries of the total amounts of codeine in tampering products of 81–84% from Product 1 (codeine/acetylsalicylic acid); 61–67% from Product 2 (codeine/ibuprofen); and 42–71% from Product 3 (codeine/paracetamol). Recoveries of non-opioid analgesics ranged between: 57–73% acetylsalicylic acid; 5.5–8.5% ibuprofen, and 5.0–9.2% paracetamol.

Conclusion

With the tampering procedures used, high amounts of codeine were separated from the accompanying analgesics in some, but not in all of the codeine containing formulations. Evidence-based medicine regulation, treatment for opioid dependence, and information to minimise risks to the public are essential components of an effective public health strategy to address the harms of tampering and misuse.

Funding

Marie Pedersen and Jensine Heiberg Foundation.
Literature
1.
go back to reference British Medical Association. Prescribed drugs associated with dependence and withdrawal—building a consensus for action. London: BMA; 2015. British Medical Association. Prescribed drugs associated with dependence and withdrawal—building a consensus for action. London: BMA; 2015.
2.
go back to reference Mounteney J, Giraudon I, Denissov G, Griffiths P. Fentanyls: are we missing the signs? Highly potent and on the rise in Europe. Int J Drug Policy. 2015;26:626–31.CrossRefPubMed Mounteney J, Giraudon I, Denissov G, Griffiths P. Fentanyls: are we missing the signs? Highly potent and on the rise in Europe. Int J Drug Policy. 2015;26:626–31.CrossRefPubMed
3.
go back to reference Advisory Council on the Misuse of Drugs. ACMD consideration of tramadol. London: ACMD; 2013. Advisory Council on the Misuse of Drugs. ACMD consideration of tramadol. London: ACMD; 2013.
4.
go back to reference Medicines and Healthcare Products Regulatory Agency. MHRA public assessment report. Codeine and dihydrocodeine-containing medicines: minimising the risk of addiction. London: MHRA; 2009. Medicines and Healthcare Products Regulatory Agency. MHRA public assessment report. Codeine and dihydrocodeine-containing medicines: minimising the risk of addiction. London: MHRA; 2009.
5.
go back to reference Griffiths P, Evans-Brown M, Sedefov R. The (mis)use of psychoactive medicines: getting the balance right in complex systems. Addiction. 2014;109:182–3.CrossRefPubMed Griffiths P, Evans-Brown M, Sedefov R. The (mis)use of psychoactive medicines: getting the balance right in complex systems. Addiction. 2014;109:182–3.CrossRefPubMed
7.
go back to reference Dale-Perera A, Goulão J, Stöver H. Quality of care provided to patients receiving opioid maintenance treatment in Europe: results from the EQUATOR analysis. Heroin Addict Relat Clin Probl. 2012;14:23–38. Dale-Perera A, Goulão J, Stöver H. Quality of care provided to patients receiving opioid maintenance treatment in Europe: results from the EQUATOR analysis. Heroin Addict Relat Clin Probl. 2012;14:23–38.
8.
go back to reference Johnson B, Richert T. Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors. Int J Drug Policy. 2015;26:183–90.CrossRefPubMed Johnson B, Richert T. Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors. Int J Drug Policy. 2015;26:183–90.CrossRefPubMed
9.
go back to reference Häkkinen M, Vuori E, Ojanperä I. Prescription opioid abuse based on representative postmortem toxicology. Forensic Sci Int. 2014;245:121–5.CrossRefPubMed Häkkinen M, Vuori E, Ojanperä I. Prescription opioid abuse based on representative postmortem toxicology. Forensic Sci Int. 2014;245:121–5.CrossRefPubMed
10.
go back to reference van Amsterdam J, van den Brink W. The misuse of prescription opioids: a threat for Europe? Curr Drug Abuse Rev. 2015;8:3–14.CrossRefPubMed van Amsterdam J, van den Brink W. The misuse of prescription opioids: a threat for Europe? Curr Drug Abuse Rev. 2015;8:3–14.CrossRefPubMed
11.
go back to reference Martins SS, Sampson L, Cerdá M, Galea S. Worldwide prevalence and trends in unintentional drug overdose: a systematic review of the literature. Am J Public Health. 2015;105:e29–49.CrossRefPubMedPubMedCentral Martins SS, Sampson L, Cerdá M, Galea S. Worldwide prevalence and trends in unintentional drug overdose: a systematic review of the literature. Am J Public Health. 2015;105:e29–49.CrossRefPubMedPubMedCentral
12.
go back to reference Simonsen KW, Edvardsen HME, Thelander G, Ojanperä I, Thordardottir S, Andersen LV, et al. Fatal poisoning in drug addicts in the Nordic countries in 2012. Forensic Sci Int. 2015;248:172–80.CrossRefPubMed Simonsen KW, Edvardsen HME, Thelander G, Ojanperä I, Thordardottir S, Andersen LV, et al. Fatal poisoning in drug addicts in the Nordic countries in 2012. Forensic Sci Int. 2015;248:172–80.CrossRefPubMed
13.
go back to reference Office for National Statistics. Statistical Bulletin. Deaths related to drug poisoning in England and Wales, 2014 registrations. London: Office for National Statistics; 2015. Office for National Statistics. Statistical Bulletin. Deaths related to drug poisoning in England and Wales, 2014 registrations. London: Office for National Statistics; 2015.
14.
go back to reference European Monitoring Centre for Drugs and Drug Addiction. European drug report. Trends and developments 2015. Lisbon: EMCDDA; 2015. European Monitoring Centre for Drugs and Drug Addiction. European drug report. Trends and developments 2015. Lisbon: EMCDDA; 2015.
15.
go back to reference Jonsson B, Backman E, Salmonson H, Höjer J. Injection of crushed tablets—a prospective observational study. Clin Toxicol. 2014;52:982–3.CrossRef Jonsson B, Backman E, Salmonson H, Höjer J. Injection of crushed tablets—a prospective observational study. Clin Toxicol. 2014;52:982–3.CrossRef
16.
go back to reference Liappas IA, Dimopoulos NP, Mellos E, Gitsa OE, Liappas AI, Rabavilas AD. Oral transmucosal abuse of transdermal fentanyl. J Psychopharmacol. 2004;18:277–80.CrossRefPubMed Liappas IA, Dimopoulos NP, Mellos E, Gitsa OE, Liappas AI, Rabavilas AD. Oral transmucosal abuse of transdermal fentanyl. J Psychopharmacol. 2004;18:277–80.CrossRefPubMed
18.
go back to reference Häkkinen M, Heikman P, Ojanperä I. Parenteral buprenorphine–naloxone abuse is a major cause of fatal buprenorphine-related poisoning. Forensic Sci Int. 2013;232:11–5.CrossRefPubMed Häkkinen M, Heikman P, Ojanperä I. Parenteral buprenorphine–naloxone abuse is a major cause of fatal buprenorphine-related poisoning. Forensic Sci Int. 2013;232:11–5.CrossRefPubMed
19.
go back to reference Roussin A, Bouyssi A, Pouché L, Pourcel L, Lapeyre-Mestre M. Misuse and dependence on non-prescription codeine analgesics or sedative H1 antihistamines by adults: a cross-sectional investigation in France. PLoS One. 2013;8:e76499.CrossRefPubMedPubMedCentral Roussin A, Bouyssi A, Pouché L, Pourcel L, Lapeyre-Mestre M. Misuse and dependence on non-prescription codeine analgesics or sedative H1 antihistamines by adults: a cross-sectional investigation in France. PLoS One. 2013;8:e76499.CrossRefPubMedPubMedCentral
20.
go back to reference Cone EJ. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet. Drug Alcohol Depend. 2006;83:S31–9.CrossRefPubMed Cone EJ. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet. Drug Alcohol Depend. 2006;83:S31–9.CrossRefPubMed
21.
go back to reference Casati A, Sedefov R, Pfeiffer-Gerschel T. Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res. 2012;18:228–45.CrossRefPubMed Casati A, Sedefov R, Pfeiffer-Gerschel T. Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res. 2012;18:228–45.CrossRefPubMed
22.
go back to reference Foley M, Breindahl T, Hindersson P, Deluca P, Kimergård A. Misuse of ‘over-the-counter’ codeine analgesics: does formulation play a role? Public Health. 2016;130:95–6.CrossRefPubMed Foley M, Breindahl T, Hindersson P, Deluca P, Kimergård A. Misuse of ‘over-the-counter’ codeine analgesics: does formulation play a role? Public Health. 2016;130:95–6.CrossRefPubMed
23.
go back to reference Foley M, Harris R, Rich E, Rapca A, Bergin M, Norman I, et al. The availability of over-the-counter codeine medicines across the European Union. Public Health. 2015;129:1465–70.CrossRefPubMed Foley M, Harris R, Rich E, Rapca A, Bergin M, Norman I, et al. The availability of over-the-counter codeine medicines across the European Union. Public Health. 2015;129:1465–70.CrossRefPubMed
24.
go back to reference Tobin CL, Dobbin M, McAvoy B. Regulatory responses to over-the-counter codeine analgesic misuse in Australia, New Zealand and the United Kingdom. Aust N Z J Public Health. 2013;37:483–8.CrossRefPubMed Tobin CL, Dobbin M, McAvoy B. Regulatory responses to over-the-counter codeine analgesic misuse in Australia, New Zealand and the United Kingdom. Aust N Z J Public Health. 2013;37:483–8.CrossRefPubMed
25.
go back to reference Frei MY, Nielsen S, Dobbin MDH, Tobin CL. Serious morbidity associated with misuse of over-the-counter codeine-ibuprofen analgesics: a series of 27 cases. Med J Aust. 2010;193:294–6.PubMed Frei MY, Nielsen S, Dobbin MDH, Tobin CL. Serious morbidity associated with misuse of over-the-counter codeine-ibuprofen analgesics: a series of 27 cases. Med J Aust. 2010;193:294–6.PubMed
26.
go back to reference Locher C, Lambare B, Fischer D, Labayle D. Acute pancreatitis induced by codeine-acetaminophen association: report of two cases. Gastroenterol Clin Biol. 2003;27:124–5.PubMed Locher C, Lambare B, Fischer D, Labayle D. Acute pancreatitis induced by codeine-acetaminophen association: report of two cases. Gastroenterol Clin Biol. 2003;27:124–5.PubMed
27.
go back to reference Alaygut D, Torun-Bayram M, Ünlü M, Soylu A, Türkmen M, Kavukçu S. Acute tubulointerstitial nephritis-uveitis (TINU) syndrome developed secondary to paracetamol and codeine phosphate use: two case reports. Turk J Pediatr. 2014;56:92–6.PubMed Alaygut D, Torun-Bayram M, Ünlü M, Soylu A, Türkmen M, Kavukçu S. Acute tubulointerstitial nephritis-uveitis (TINU) syndrome developed secondary to paracetamol and codeine phosphate use: two case reports. Turk J Pediatr. 2014;56:92–6.PubMed
28.
go back to reference Dutch MJ. Nurofen Plus misuse: an emerging cause of perforated gastric ulcer. Med J Aust. 2008;188:56–7.PubMed Dutch MJ. Nurofen Plus misuse: an emerging cause of perforated gastric ulcer. Med J Aust. 2008;188:56–7.PubMed
30.
go back to reference Torper J, Steine S. Patients’ experience with withdrawal of addictive drugs. Tidsskr Nor Laegeforen. 2004;124:2342–4.PubMed Torper J, Steine S. Patients’ experience with withdrawal of addictive drugs. Tidsskr Nor Laegeforen. 2004;124:2342–4.PubMed
31.
go back to reference Paterson JR, Talwar DK, Watson ID, Stewart MJ, Sakol MS, Stark CR. Codeine abuse from co-codaprin. Lancet. 1990;335:224.CrossRefPubMed Paterson JR, Talwar DK, Watson ID, Stewart MJ, Sakol MS, Stark CR. Codeine abuse from co-codaprin. Lancet. 1990;335:224.CrossRefPubMed
33.
go back to reference Donuk T, Altıntoprak AE, Tekin H. Possible causal link between idiopathic intracranial hypertension and the misuse of codeine-based products. J Child Adolesc Psychopharmacol. 2015. [Epub ahead of print 28 July 2015]. Donuk T, Altıntoprak AE, Tekin H. Possible causal link between idiopathic intracranial hypertension and the misuse of codeine-based products. J Child Adolesc Psychopharmacol. 2015. [Epub ahead of print 28 July 2015].
35.
go back to reference Haynes A, Kleinschmidt K, Forrester MB, Young A. Trends in analgesic exposures reported to Texas Poison Centers following increased regulation of hydrocodone. Clin Toxicol. 2016;54:434–40. Haynes A, Kleinschmidt K, Forrester MB, Young A. Trends in analgesic exposures reported to Texas Poison Centers following increased regulation of hydrocodone. Clin Toxicol. 2016;54:434–40.
36.
go back to reference Fingleton NA, Watson MC, Duncan EM, Matheson C. Non-prescription medicine misuse, abuse and dependence: a cross-sectional survey of the UK general population. J Public Health. 2016. [Epub ahead of print 2 February 2016]. Fingleton NA, Watson MC, Duncan EM, Matheson C. Non-prescription medicine misuse, abuse and dependence: a cross-sectional survey of the UK general population. J Public Health. 2016. [Epub ahead of print 2 February 2016].
37.
go back to reference Kean J. Illicit and over-the-counter codeine dependence after acute back pain- successful treatment and ongoing recovery after buprenorphine/naloxone taper. Heroin Addict Relat Clin Probl. 2016;18:21–4. Kean J. Illicit and over-the-counter codeine dependence after acute back pain- successful treatment and ongoing recovery after buprenorphine/naloxone taper. Heroin Addict Relat Clin Probl. 2016;18:21–4.
38.
39.
go back to reference International Narcotics Control Board. Estimated world requirements for 2015: statistics for 2013. New York: United Nations; 2014. International Narcotics Control Board. Estimated world requirements for 2015: statistics for 2013. New York: United Nations; 2014.
40.
go back to reference Cooper R. Surveillance and uncertainty: community pharmacy responses to over the counter medicine abuse. Health Soc Care Comm. 2013;21:254–62.CrossRef Cooper R. Surveillance and uncertainty: community pharmacy responses to over the counter medicine abuse. Health Soc Care Comm. 2013;21:254–62.CrossRef
41.
go back to reference Sellers EM, Perrino PJ, Colucci SV, Harris SC. Attractiveness of reformulated OxyContin® tablets: assessing comparative preferences and tampering potential. J Psychopharmacol. 2013;27:808–16.CrossRefPubMed Sellers EM, Perrino PJ, Colucci SV, Harris SC. Attractiveness of reformulated OxyContin® tablets: assessing comparative preferences and tampering potential. J Psychopharmacol. 2013;27:808–16.CrossRefPubMed
42.
go back to reference Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Shapiro DY, Comer SD. A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers. Addiction. 2013;108:1095–106.CrossRefPubMedPubMedCentral Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Shapiro DY, Comer SD. A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers. Addiction. 2013;108:1095–106.CrossRefPubMedPubMedCentral
43.
go back to reference Bedford KR, Nolan SL, Onrust R, Siegers JD. The illicit preparation of morphine and heroin from pharmaceutical products containing codeine: ‘homebake’ laboratories in New Zealand. Forensic Sci Int. 1987;34:197–204.CrossRefPubMed Bedford KR, Nolan SL, Onrust R, Siegers JD. The illicit preparation of morphine and heroin from pharmaceutical products containing codeine: ‘homebake’ laboratories in New Zealand. Forensic Sci Int. 1987;34:197–204.CrossRefPubMed
44.
go back to reference Fleming GF, McElnay JC, Hughes CM. The separation of codeine from nonprescription combination analgesic products. Subst Use Misuse. 2003;38:1217–26.CrossRefPubMed Fleming GF, McElnay JC, Hughes CM. The separation of codeine from nonprescription combination analgesic products. Subst Use Misuse. 2003;38:1217–26.CrossRefPubMed
45.
go back to reference Jensen S, Hansen AC. Abuse of codeine separated from over-the-counter drugs containing acetylsalicylic acid and codeine. Int J Legal Med. 1993;105:279–81.CrossRefPubMed Jensen S, Hansen AC. Abuse of codeine separated from over-the-counter drugs containing acetylsalicylic acid and codeine. Int J Legal Med. 1993;105:279–81.CrossRefPubMed
49.
go back to reference Harris SC, Perrino PJ, Smith I, Shram MJ, Colucci SV, Bartlett C, et al. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. J Clin Pharmacol. 2013;54:468–77.CrossRefPubMed Harris SC, Perrino PJ, Smith I, Shram MJ, Colucci SV, Bartlett C, et al. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. J Clin Pharmacol. 2013;54:468–77.CrossRefPubMed
50.
go back to reference Larance B, Lintzeris N, Bruno R, Peacock A, Cama E, Ali R, et al. The characteristics of a cohort who tamper with prescribed and diverted opioid medications. J Subst Abuse Treat. 2015;58:51–61.CrossRefPubMed Larance B, Lintzeris N, Bruno R, Peacock A, Cama E, Ali R, et al. The characteristics of a cohort who tamper with prescribed and diverted opioid medications. J Subst Abuse Treat. 2015;58:51–61.CrossRefPubMed
51.
go back to reference Kimergård A, Breindahl T, Hindersson P, Deluca P. Tampering of opioid analgesics: a serious challenge for public health? Addiction. 2016 (in press). Kimergård A, Breindahl T, Hindersson P, Deluca P. Tampering of opioid analgesics: a serious challenge for public health? Addiction. 2016 (in press).
56.
go back to reference Wright C, Schnoll S, Bernstein D. Risk evaluation and mitigation strategies for drugs with abuse liability. Ann N Y Acad Sci. 2008;1141:284–303.CrossRefPubMed Wright C, Schnoll S, Bernstein D. Risk evaluation and mitigation strategies for drugs with abuse liability. Ann N Y Acad Sci. 2008;1141:284–303.CrossRefPubMed
57.
go back to reference Tohgi H, Konno S, Tamura K, Kimura B, Kawano K. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke. 1992;23:1400–3.CrossRefPubMed Tohgi H, Konno S, Tamura K, Kimura B, Kawano K. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke. 1992;23:1400–3.CrossRefPubMed
58.
go back to reference Schou M, Svennum V. Acute salicylate poisoning may cause non-cardiogenic pulmonary edema. Lakartidningen. 2012;109:700–1.PubMed Schou M, Svennum V. Acute salicylate poisoning may cause non-cardiogenic pulmonary edema. Lakartidningen. 2012;109:700–1.PubMed
59.
go back to reference Løgstrup BB, Øgaard S. Hypokalaemia as a result of abuse of Kodimagnyl. Ugeskr Laeger. 2007;169:520.PubMed Løgstrup BB, Øgaard S. Hypokalaemia as a result of abuse of Kodimagnyl. Ugeskr Laeger. 2007;169:520.PubMed
60.
go back to reference Christiansen MH, Thomsen AH, Andersen LV. Chronic salicylate poisoning is a challenging diagnosis. Ugeskr Laeger. 2015;177:1151–2.PubMed Christiansen MH, Thomsen AH, Andersen LV. Chronic salicylate poisoning is a challenging diagnosis. Ugeskr Laeger. 2015;177:1151–2.PubMed
61.
go back to reference Gabow PA, Anderson RJ, Potts DE, Schrier RW. Acid–base disturbances in the salicylate-intoxicated adult. Arch Intern Med. 1978;138:1481–4.CrossRefPubMed Gabow PA, Anderson RJ, Potts DE, Schrier RW. Acid–base disturbances in the salicylate-intoxicated adult. Arch Intern Med. 1978;138:1481–4.CrossRefPubMed
62.
go back to reference Howard LA, Sellers EM, Tyndale RF. The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. Pharmacogenomics. 2002;3:185–99.CrossRefPubMed Howard LA, Sellers EM, Tyndale RF. The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. Pharmacogenomics. 2002;3:185–99.CrossRefPubMed
63.
go back to reference Roux P, Carrieri MP, Keijzer L, Dasgupta N. Reducing harm from injecting pharmaceutical tablet or capsule material by injecting drug users. Drug Alcohol Rev. 2011;30:287–90.CrossRefPubMed Roux P, Carrieri MP, Keijzer L, Dasgupta N. Reducing harm from injecting pharmaceutical tablet or capsule material by injecting drug users. Drug Alcohol Rev. 2011;30:287–90.CrossRefPubMed
64.
go back to reference Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarone D. “Every ‘Never’ I Ever Said Came True”: transitions from opioid pills to heroin injecting. Int J Drug Policy. 2014;25:257–66.CrossRefPubMed Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarone D. “Every ‘Never’ I Ever Said Came True”: transitions from opioid pills to heroin injecting. Int J Drug Policy. 2014;25:257–66.CrossRefPubMed
65.
go back to reference Centers for Disease Control and Prevention. Today’s heroin epidemic. Atlanta: Centers for Disease Control and Prevention; 2015. Centers for Disease Control and Prevention. Today’s heroin epidemic. Atlanta: Centers for Disease Control and Prevention; 2015.
66.
go back to reference Warner M, Hedegaard H, Chen L-H. Trends in drug-poisoning deaths involving opioid analgesics and heroin: United States, 1999–2012. Hyattsville: CDC/National Center for Health Statistics; 2014. Warner M, Hedegaard H, Chen L-H. Trends in drug-poisoning deaths involving opioid analgesics and heroin: United States, 1999–2012. Hyattsville: CDC/National Center for Health Statistics; 2014.
67.
go back to reference Conroy S, Hill D. Failure to identify or effectively manage prescription opioid dependence acted as a gateway to heroin use—buprenorphine/naloxone treatment and recovery in a surgical patient. BMJ Case Rep. 2014. doi: 10.1136/bcr-2014-207458. Conroy S, Hill D. Failure to identify or effectively manage prescription opioid dependence acted as a gateway to heroin use—buprenorphine/naloxone treatment and recovery in a surgical patient. BMJ Case Rep. 2014. doi: 10.​1136/​bcr-2014-207458.
68.
go back to reference Lourenço LM, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use? Expert Opin Drug Deliv. 2013;10:229–40.CrossRefPubMed Lourenço LM, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use? Expert Opin Drug Deliv. 2013;10:229–40.CrossRefPubMed
69.
go back to reference Raffa RB, Pergolizzi JV. Opioid formulations designed to resist/deter abuse. Drugs. 2010;70:1657–75.CrossRefPubMed Raffa RB, Pergolizzi JV. Opioid formulations designed to resist/deter abuse. Drugs. 2010;70:1657–75.CrossRefPubMed
Metadata
Title
How Resistant to Tampering are Codeine Containing Analgesics on the Market? Assessing the Potential for Opioid Extraction
Authors
Andreas Kimergård
Paolo Deluca
Peter Hindersson
Torben Breindahl
Publication date
01-12-2016
Publisher
Springer Healthcare
Published in
Pain and Therapy / Issue 2/2016
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-016-0053-2

Other articles of this Issue 2/2016

Pain and Therapy 2/2016 Go to the issue